Hjem › Spiserørkreft › Pennsylvania › Pittsburgh
Kliniske studier for Spiserørkreft i Pittsburgh, PA
15 studier for Spiserørkreft søker deltakere på steder i og rundt Pittsburgh (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
RekruttererFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 4904), Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Rekrutterer
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekruttererFase 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
RekruttererFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RekruttererFase 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RekruttererFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 8904), Pittsburgh
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RekruttererFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 6904), Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
RekruttererFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
Rekrutterer
- UPMC Hillman Cancer Center, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RekruttererFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Esophageal Cancer Risk Registry
RekruttererObservasjonsstudie
- Department of Cardiothoracic Surgery, Pittsburgh
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
RekruttererObservasjonsstudie
- University of Pittsburgh Medical Center - Department of Cardiothoracic Surgery, Pittsburgh
- UPMC - Hillman Cancer Center, Pittsburgh
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
RekruttererObservasjonsstudie
- Allegheny Health Network, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RekruttererFase 1
- AHN West Penn Hospital, Pittsburgh
Spiserørkreft-studier i andre byer
- Houston, TX36 studier
- Boston, MA23 studier
- New York City, NY22 studier
- Nashville, TN19 studier
- St. Louis, MO17 studier
- Los Angeles, CA15 studier
- Baldwin Park, CA14 studier
- Grand Rapids, MI14 studier
- Philadelphia, PA13 studier
- San Antonio, TX12 studier
- Rochester, MN11 studier
- Arlington, VA11 studier
Andre studier i Pittsburgh
- Ikke-småcellet lungekreft48 studier
- Kreft (alle typer)41 studier
- Brystkreft39 studier
- Kolorektal kreft32 studier
- Metastatisk kreft31 studier
- Melanom31 studier
- Eggstokkreft30 studier
- Endometriekreft23 studier
- Prostatakreft23 studier
- Lungekreft23 studier
- Plateepitelcancer i hode og hals22 studier
- Slag22 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.